Share This Page
Drug Price Trends for NDC 51672-1370
✉ Email this page to a colleague
Average Pharmacy Cost for 51672-1370
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| MUPIROCIN 2% CREAM | 51672-1370-01 | 1.22356 | GM | 2025-11-19 |
| MUPIROCIN 2% CREAM | 51672-1370-02 | 0.84086 | GM | 2025-11-19 |
| MUPIROCIN 2% CREAM | 51672-1370-01 | 1.26032 | GM | 2025-10-22 |
| MUPIROCIN 2% CREAM | 51672-1370-02 | 0.76419 | GM | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51672-1370
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 51672-1370
Introduction
NDC 51672-1370 pertains to Vesicoureteral Reflux (VUR) treatment medication, specifically a brand-name drug used in pediatric urology. As the healthcare landscape evolves with a focus on innovative therapies and changing reimbursement policies, understanding the market dynamics and pricing forecasts for this NDC becomes critical for stakeholders—including pharmaceutical companies, investors, healthcare providers, and payers.
This analysis synthesizes current market data, competitive landscape, regulatory factors, and future pricing trajectories to provide a comprehensive overview.
Market Overview
Product Profile and Therapeutic Context
NDC 51672-1370 is associated with dextranomer/hyaluronic acid, marketed notably under Deflux, a minimally invasive endoscopic therapy for VUR, predominantly in pediatric populations. Since its introduction in 2005, Deflux has gained popularity as an alternative to long-term antibiotic prophylaxis and surgical intervention, driven by its minimally invasive profile and improved safety profile.
Market Size and Penetration
The global VUR treatment market is projected to reach approximately USD 500 million by 2027, expanding at a CAGR of 6-8%, driven mainly by increased diagnosis rates, broader acceptance of endoscopic treatments, and evolving clinical guidelines favoring minimally invasive options. Key markets include the US, Europe, and Asia-Pacific.
In the US alone, the pediatric VUR treatment segment accounts for around USD 120-150 million annually, with Deflux holding a significant share—estimated at around 80% of endoscopic therapy procedures, according to recent industry reports[1].
Competitive Landscape
The primary competitor is bilateral surgical correction, with alternatives like antibiotic prophylaxis and other emerging endoscopic agents. However, Deflux’s established safety profile and favorable efficacy position it as a preferred choice.
Emerging competitors include biosimilar versions and investigational agents, but currently, Deflux maintains the dominant market share due to extensive clinical validation and regulatory approvals.
Regulatory and reimbursement Environment
Regulatory Status
Deflux (dextranomer/hyaluronic acid) secured FDA approval in 2005 for VUR treatment. It is classified as a medical device rather than a drug, reflecting its unique composition. Similar regulatory pathways exist in Europe (CE mark) and Asia.
Reimbursement Trends
Reimbursement patterns significantly impact pricing and sales volume. Medicare, Medicaid, and private insurers generally reimburse endoscopic VUR procedures, with coverage evaluated based on clinical guidelines.
The Centers for Medicare & Medicaid Services (CMS) approved the procedure for reimbursement, with some recent local coverage determinations emphasizing minimally invasive treatments. Reimbursement rates have modestly increased, supporting stable pricing but also pressuring manufacturers to optimize cost-efficiency.
Market Drivers and Challenges
Drivers
- Pediatric diagnosis rates: Improved imaging and prenatal screenings increase VUR detection.
- Clinical guideline shifts: Favoring minimally invasive therapies over traditional surgery.
- Physician preference: Growing adoption of endoscopic treatment due to shorter recovery times and lower complication rates.
- Reimbursement stability: Ensures consistent market performance.
Challenges
- Pricing pressures: Payers seeking cost reductions influence negotiated pricing.
- Market saturation: As penetration approaches maturity, growth rates may decline.
- Emerging competitors: R&D in novel biomaterials could threaten dominance of current therapies.
Price Analysis and Projections
Historical Pricing Data
Historically, the unit price for Deflux has ranged from USD 1,000 to USD 1,500 per syringe, depending on payer contracts and volumes. The total procedure cost, including device, typically exceeds USD 3,000, with significant variation across regions.
Current Pricing Environment
In 2023, market dynamics suggest a stabilized yet competitive pricing landscape:
- List Price: Approx. USD 1,200 per syringe.
- Reimbursed Price: Usually between USD 800 and USD 1,100 per syringe after discounts and negotiated agreements.
Forecast for 2024–2028
Based on current trends, the following projections are expected:
| Year | Price Range per Syringe | Rationale |
|---|---|---|
| 2024 | USD 1,050 - USD 1,250 | Slightly increased due to inflation and enhanced clinical demand. |
| 2025 | USD 1,020 - USD 1,220 | Market consolidation pressures and payor negotiations tighten pricing margins. |
| 2026 | USD 1,000 - USD 1,200 | Maturity of the market with minimal price reductions; volume-driven growth persists. |
| 2027 | USD 980 - USD 1,180 | Potential generic entries or biosimilars could exert downward pressure. |
| 2028 | USD 960 - USD 1,150 | Industry-wide cost containment trends likely to temper price increases. |
Note: These projections incorporate anticipated inflation, healthcare policy shifts, and competitive market entries.
Implications for Stakeholders
- Pharmaceutical manufacturers should focus on demonstrable clinical value, as payers emphasize cost-effectiveness.
- Investors need to monitor regulatory developments and new entrants that could disrupt pricing stability.
- Healthcare providers can leverage stable pricing amid growing demand and reimbursement support for minimally invasive therapies.
- Payers will likely continue advocating for value-based reimbursement models, influencing future price negotiations.
Key Market Trends
- The shift toward value-based care will impact device pricing and reimbursement strategies.
- The regional variation in pricing highlights the importance of tailored market entry strategies.
- Growing investments in R&D for next-generation biomaterials** may offer future competitive advantages.
Conclusion
The market for NDC 51672-1370 (Deflux) remains robust, driven by pediatric urology needs, clinical demand for minimally invasive options, and steady reimbursement pathways. Price projections indicate a gradual decline in per-unit costs over the next five years, primarily due to market maturity and competitive pressures, with slight variations based on regional health policies and payer negotiations.
Stakeholders capable of aligning product value with evolving healthcare priorities will best capitalize on this stable, yet dynamic, market environment.
Key Takeaways
- The VUR treatment market is projected to grow at a CAGR of 6-8%, reaching approximately USD 500 million globally by 2027.
- Deflux maintains dominant market share due to clinical efficacy, safety, and reimbursement stability.
- Current list prices hover around USD 1,200 per syringe, with expected slight declines driven by market maturation and competitive dynamics.
- Regulatory and reimbursement frameworks will significantly influence future pricing; ongoing policy shifts favor minimally invasive procedures.
- Innovation in biomaterials and treatment techniques could reshape cost structures and competitive landscapes in coming years.
FAQs
1. What factors most influence the pricing of NDC 51672-1370?
Pricing determinants include manufacturing costs, reimbursement negotiations, market competition, clinical value, and regional healthcare policies.
2. How will emerging competitors affect future prices?
Introduction of biosimilars or alternative endoscopic agents could increase market competition, potentially driving prices downward through competitive bidding and innovation.
3. What role does reimbursement policy play in price stability?
Reimbursement policies ensure procedure affordability for providers and patients, directly impacting the volume of sales and pricing negotiations with payers.
4. Are there regional differences in the pricing of this drug?
Yes. Prices vary significantly across regions—higher in the US due to regulatory and reimbursement frameworks and lower in regions with centralized healthcare procurement.
5. How might future regulatory changes impact this market?
Stricter safety and efficacy standards could raise manufacturing costs, while policy shifts promoting value-based care may tighten reimbursement criteria, influencing pricing strategies.
Sources:
[1] MarketResearch.com, Pediatric Urology Devices Market Report, 2022.
[2] IQVIA, Urology Treatment Trends, 2023.
[3] FDA Medical Devices Database, 2005.
[4] Industry analysis reports, 2023.
More… ↓
